AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.
Warngau, Germany, and Coventry, Great Britain, October 25, 2022
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.
Under the terms of the agreement, Mistral will distribute goserelin and leuprorelin within the licensed territory. AMW will manufacture and supply goserelin and leuprorelin under pre-agreed terms and will receive royalty payments on Mistral’s net sales.
“We are extremely pleased that our goserelin and leuprorelin implants are being distributed to patients in Ukraine and beyond by our partner Mistral, who has a deep understanding of European and Asian markets,” commented Dr. Konstantin Petropoulos, CEO of AMW. “This agreement contributes to our objective of providing as many patients as possible access to our improved and cost-effective therapies.”
“We are proud to partner with AMW, building up a trustful relationship for the patients’ benefit,” added Andrii Astakhov, Director Business Development of Mistral. “We see a common goal in Mistral’s mission of delivering a wide portfolio of innovative, affordable healthcare products and services of the highest quality, and build upon the latest developments in medical science.” AMW develops and produces innovative, bio-degradable sustained-release drug delivery systems, such as the GnRH analogue implants goserelin and leuprorelin. For global commercialization, the products are licensed to international and regional partners. AMW is the exclusive manufacturer and provider of these implants and also receives royalties on licenses from its partners. To date, goserelin has been licensed to leading global and local pharmaceutical enterprises in more than 50 countries. In Germany, AMW’s products are distributed by the Company’s wholly owned subsidiary Endomedica GmbH.
About AMW:
AMW GmbH is a specialty pharmaceutical company focused on innovative bio-degradable sustained-release drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology. AMW currently has four marketed products (goserelin & leuprorelin implants, rivastigmine & buprenorphine patches).
AMW is based in Warngau, south of Munich, Germany.
About Mistral Capital Management:
Mistral Capital Management LTD is a pharmaceutical company operating through its distributors in Ukraine and ex-CIS countries bringing modern and innovative products of the highest quality, striving to be as a first generic in the target markets.
Our ultimate goal is to provide our business partners with a full range of services to achieve outstanding results.
Our top priority is the highest satisfaction of our customers’ needs.
About Goserelin and Leuprorelin:
Goserelin and Leuprorelin implants contain the active ingredients goserelin and leuprorelin, respectively, and belong to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormone-dependent tumors such as prostate cancer or breast cancer. In addition, goserelin is used to treat certain benign gynecological disorders. Both are administered in the form of a biodegradable implant which releases the active ingredient over a period of either one or three months.
For further information, please contact:
AMW GmbH
Dr. Konstantin Petropoulos
Phone: +49 8024 470999-0
Email: news@a-m-w.eu